Black Diamond Therapeutics (BDTX) Free Cash Flow Growth (3y) (2022 - 2026)

Black Diamond Therapeutics (BDTX) Free Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -5.05%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 31.07%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 14.71%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -10.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Black Diamond Therapeutics 99.59 Mn -18.67 Mn - 20.18%

Historic Data

Download Data
DateValue
Mar 31, 2026 20.18%
Dec 31, 2025 32.51%
Sep 30, 2025 22.34%
Jun 30, 2025 20.40%
Mar 31, 2025 56.99%
Dec 31, 2024 14.44%
Sep 30, 2024 23.89%
Jun 30, 2024 16.70%
Mar 31, 2024 4.64%
Dec 31, 2023 4.21%
Sep 30, 2023 -17.00%
Jun 30, 2023 -1.88%
Mar 31, 2023 -20.96%
Dec 31, 2022 -43.09%
Sep 30, 2022 -46.32%
Jun 30, 2022 -53.49%
Mar 31, 2022 -60.72%